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Abstract
Cardiac cachexia is a serious complication of chronic heart failure with a prevalence of 10–16% and poor prognosis. There
are no current therapy options for cardiac cachexia. Ghrelin is the natural ligand for the GHS-1a-receptor and a potential
target for conditions associated with cachexia. Ghrelin has been shown to increase weight in several species. The GHS-1a-
receptor is not only found in the brain, but also in other tissues, including the myocardium. Human clinical trials with native
ghrelin in cardiac cachexia demonstrated increases in appetite, weight and cardiac output.
Methods: Human ghrelin or one of two analogues BIM-28125 and BIM-28131 (also known as RM-131) were tested at 50 nmole/
kg/d and 500 nmole/kg/d versus placebo in a rat model of heart failure (myocardialinfarction). Animals (SD-rats, approx. 225 g at
surgery) received diuretics from day 14 and compounds from day 28 for 4 weeks using osmotic pumps. Weight was monitored
and body composition analysed (NMR-scanning). Cardiac function was assessed by echocardiography and hemodynamics.
Results: Animals with MI gained less weight compared to sham rats until start of the therapy (311 g vs 324 g, p=0.0129).
Animals treated with BIM-28131 at 50 nmole/kg/d or all compounds at 500 nmole/kg/d displayed stronger weight gain
compared to placebo and sham (all p,0.001). Before treatment, body composition was similar in all groups (average: 36 g
fat, 248 g lean). Placebo-treated rats gained no fat, but only lean mass. The active compounds induced both fat and lean
mass gain, but to a different extent. The fat-to-muscle-ratio of tissue gain was 0.960.07 for BIM-28131 at 50 nmole/kg/d,
whereas at 500 nmole/kg/d it was 0.7660.07 for BIM-28131, 0.6860.12 for BIM-28125, and 0.4860.05 for ghrelin. MuRF-1
and MAFbx were differentially regulated by treatment.
Conclusion: Ghrelin is a very promising treatment option for cardiac cachexia, with the analogue BIM-28131 (RM-131) being
the most effective compound.
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Introduction
Heart failure is one of the major public health problems, which
currently affects over 5 million Americans with 500,000 new cases
per year. Clinical trials have shown that beta-blockers [1] and
angiotensin-converting enzyme inhibitors [2] reduce the mortality
in patients with chronic heart failure (CHF), but CHF still
contributes to 250,000 deaths per year. Approximately 15% of the
CHF patients display cardiac cachexia, which further impairs the
mean survival (50% mortality at 18 months vs. 5 years in non-
cachectic patients) [3,4]. Cardiac cachexia represents a catabolic
state, which is characterized by a non-oedematous weight loss of
more than 6% over a period of .6 months, which affects not only
fat, but also lean mass [5]. The weight loss itself represents a strong
independent risk factor for CHF patients [3]. The anabolic growth
hormone (GH) and its mediator insulin-like growth factor-1 (IGF-
1) are essential for the metabolic homeostasis as well as muscle
growth and function. The GH/IGF-1 axis is thought to play a
major role in cardiac cachexia, as patients have increased serum
GH-levels while IGF-1 is normal or lower [6,7].
In patients suffering from cardiac cachexia, the alterations of
skeletal muscle physiology are associated with a reduction of local
IGF-expression [8], while plasma levels appear normal. At the
same time, catabolic pathways are activated. Three different
pathways are involved in protein degradation of skeletal muscle:
lysosomal degradation, calcium-activated proteases, and ATP-
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ubiquitin-proteasome pathway (UPS) is vital for the degradation of
contractile proteins leading to atrophy if activated inappropriately
[11]. A comparison of normal and atrophic rat skeletal muscle
showed that two genes were significantly upregulated during the
development of atrophy: MuRF1 (for Muscle Ring Finger 1) and
atrogin1/MAFbx (for Muscle Atrophy F-box) [12].
Ghrelin is the natural ligand for the GHS-1a receptor and a
potential target for treatment of clinical conditions associated with
energy balance and cachexia. Administration of ghrelin has been
shown to promote increased weight gain and also improve cardiac
function in mice, rats, dogs and humans. The GHS-1a receptor
and it mRNA are not only restricted to the hypothalamus and the
pituitary gland, but are also located in other tissues, including the
myocardium. Human clinical trials conducted with native ghrelin
in cachexia associated with cardiac cachexia demonstrate increases
in appetite, weight and cardiac output without apparent toxicity.
Ghrelin may therefore be an important mediator of metabolic
homeostasis and hence the GHSR a potential therapeutic target for
cachexia. Aside from metabolic benefits and regulation of feeding
behaviour [13], ghrelin has shown some beneficial cardiovascular
effects in animal studies [14] as well as human pilot trials [15],
making ghrelin an important treatment option for cardiac cachexia.
In this study, two ghrelin-analogues (BIM-28125 and BIM-
28131) were tested against human ghrelin in a randomized,
placebo-controlled, blinded rat study using the LAD myocardial
infarction model. The main focus of this study was the change in
body weight and body composition (assessed by NMR-scans) by
the treatment of the ghrelin-analogues.
Methods
CHF-Model
Myocardial infarction was induced in male Sprague Dawley rats
(Harlan-Winkelman, Borchen, Germany) weighing 215 to 230 g by
left coronary artery ligation. Control animals underwent a sham
operation consistingof a thoracotomy and cardiac exposurewithout
ligation of the coronary artery. Surgery was performed under sterile
conditions using ketamin/domitor anesthesia. After surgery,
domitor was antagonized with antisedan. All rats were treated with
buprenorphin twice daily for two days. The 24 hour mortality rate
was 31% and the surviving animals were individually housed and
maintained on standard chow with a standard 12-hour light cycle.
Starting on day 14 after surgery animals were treated with
furosemide (86 mg/L in drinking water). On day 28 the rats were
randomizedinto7treatmentgroups(n=18each),whichweregiven
either placebo or one of the ghrelin compounds BIM 28125, BIM
28131 or human ghrelin at 50 or 500 nmole/kg/d (all compounds
IPSEN Pharmaceuticals) via osmotic mini pumps (Charles River,
Sulzfeld, Germany). Pumps were implanted subcutaneously on the
back. The sham-group (n=14) received placebo (Figure S1). Pumps
were replaced on day 42 and the animals sacrificed on day 56.
Animals with an infarct size of less than 25% of the left ventricle
were excluded from this study (n=5). All procedures have been
approved by the local ethics committee (Ladesamt fu ¨r Gesundheit
und Soziales Berlin, Germany; permit number G 0116/05).
Body composition
Body weight and food intake of the animals were recorded twice
per week. Body composition was analyzed by NMR scans
(EchoMRI-700, Echo Medical System, Houston, USA) before
surgery, on day 28 and on day 56. Measures were fat mass, lean
mass,totalwaterandfree watercontent.Ameanof3 measurements
per animals was used.
Echocardiography
Echocardiography was performed prior to sacrifice, using am
15 MHz probe and an Acuson Sequoia system (Siemens, Erlangen,
Germany). Anterior and posterior end-diastolic and end-systolic wall
thickness, left-ventricular end-diastolic and end-systolic dimensions,
ejection fraction as well as fractional shortening were measured.
Hemodynamics
Hemodynamic studies were performed after 4 weeks of
treatment under chloralhydate anesthesia. A polyethylene-50
tubing catheter was inserted via the right carotid artery into the
left ventricle for measurement of mean arterial and end-diastolic
pressures. Left ventricular contractility (dP/dtmax), end-systolic and
end-diastolic pressure were obtained from the ventricular pressure
curves, which were converted with a Gould differentiator (G4615).
All pressures were registered with a Statham P23 XL transducer
and a Gould AMP 4600 amplifier. Heart rate was derived from
the arterial blood pressure signal.
Quantification of MAFbx and MuRF-1 expression
Frozen gastrocenmius samples were homogenized in lysis buffer
and protein expression was quantified by Western blot using
Table 1. Animal characteristics and body weight.
50 nmole/kg/d 500 nmole/kg/d ANOVA
Sham
Placebo Placebo BIM-28125 BIM-28131 hum ghrelin BIM-28125 BIM-28131 hum ghrelin
p-values
(infarct
groups)
Infarct size [%] - 44.562.3 39.762.4 42.461.9 4262.2 41.062.4 44.461.7 44.461.9 0.713
Tibia length [cm] 3.9460.04 3.8060.03 3.8760.15 3.9360.04 3.8960.03 3.8060.05 3.8360.03 3.8860.03 0.515
Weight at surgery [g] 227.962.5 225.062.1 227.661.6 230.462.1 227.461.6 225.262.3 226.761.9 225.662.0 0.512
Weight start treatment [g] 322.567.4 311.465.8 308.866.9 324.266.9 316.163.7 303.265.5 313.765.6 302.766.2 0.053
Weight day 42 [g] 343.367.4 338.467.6 332.666.5 366.366.9* 338.865.3 353.667.7 370.768.6** 349.368.5 0.002
Weight day 56 [g] 357.867.8 339.467.5 348.16.4 386.968.8*** 352.265.4 376.669.5** 392.368.9*** 370.9610.7* 0.001
*:p ,0.05,
**:p ,0.01,
***:p ,0.001 vs placebo.
doi:10.1371/journal.pone.0026865.t001
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group as described [16]). After incubation with a horseradish
peroxidase-conjugated secondary antibody, specific bands were
visualized by enzymatic chemiluminescence (Super Signal West
Pico, Pierce, Bonn, Germany) and densitometry was quantified
using a 1D scan software package (Scanalytics, Rockville, USA).
Loading differences were controlled by re-probing the blot with an
antibody against GAPDH (Hytest, Turku, Finland) [17].
Statistical Analysis
Numerical values are expressed as mean 6 SEM. Comparison
of parameters among the 7 groups were made using SPSS 12.0
with a one-way ANOVA, followed by the Tukey post-hoc test. A
value of p#0.05 was considered significant. Comparison of weight
gain within one group was calculated with a paired t-test.
Results
Animal characteristics
Body weight was similar at the surgery, but infracted animals
gained less weight during the first 28 days of the protocol. Body
weight at the start of treatment (day 28) was significantly lower in
animals receiving infarct surgery (311.862.0 g, n=124) as
compared to sham surgery (324.064.4 g, n=14), p=0.049,
95%CI: 224.2 to 20.2. Infarct size and tibia length were similar
between the groups (Table 1).
Weight gain
There was no significantly different increase in body weight in
the infarct groups during the first 28 days after surgery (Table 1).
On day 42 of the protocol, 2 weeks after starting the treatment
with the ghrelin-compounds or placebo, animals receiving either
BIM-28131 at 50 nmole/kg/d or BIM 28125, BIM 28131 or
human ghrelin at 500 nmole/kg/d showed a significantly stronger
weight gain compared to placebo-treated rats and even animals
with sham surgery (Table 1, Figure 1). Increasing the BIM 28131
dose 10-times did not result in a significantly higher weight gain
compared to the low dose. The weight gain was significantly
higher during day 28–36 compared to the weight gain observed
day 42–50 in the high dose groups (Figure 2). Interestingly, this
effect is not statistically relevant in the low dose groups.
Food Intake
Overall the food intake per day adjusted to body weight was
getting lower during the 2 treatment periods (period 1: day 28–41,
Figure 1. Body weight gain [g] during treatment with ghrelin
compounds or placebo (day 28–56). A dose-dependent effect of all
compounds was seen. Interestingly, 50 nmole/kg/d BIM-28131 has a
higher efficacy than BIM-21125 or human ghrelin at the same dose.
doi:10.1371/journal.pone.0026865.g001
Figure 2. Fold increase of body weight normalised to increase
in body weight in the infarct placebo group (=normal weight
gain, i.e. growth) during the first treatment period (day 28–41)
and the second treatment period (day 42–56). The first week after
pump implantation was chosen for analysis, as the dose/kg becomes
lower during treatment due to growth of the animal. Human ghrelin
shows tolerance effects, as weight gain during the second period is not
significant vs placebo. *: p,0.05, **: p,0.01, ***: p,0.001 compared to
placebo.
doi:10.1371/journal.pone.0026865.g002
Figure 3. Effect of ghrelin compounds on food intake. A) food
intake relative to overall body weight; B) gain of body weight relative to
food intake.
doi:10.1371/journal.pone.0026865.g003
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low dose BIM-28131 groups compared to placebo during treatment
period 1 (day 28–41, Figure 3), and in the second treatment period all
groups given ghrelin compounds had a higher food consumption
than placebo (figure 3). Low dose BIM-28131 (6.2660.07%) was
superior to low dose human ghrelin (5.72610.1%, p,0.001) and low
dose BIM-28125 (5.8060.07%, p,0.001) during the first but not the
second treatment period. High dose BIM 28131 (6.6660.13% and
5.4960.1 for period 1 and 2 respectively) was superior high dose
human ghrelin (6.3560.12%, p,0.01 and 5.1760.13%, p,0.01)
and BIM-28131 (6.3960.11%, p,0.01 and 5.2860.08, p,0.05).
Whileall3compoundsshoweddosedependanteffectsduringthefirst
period (all p,0.001), only BIM-28131 showed a dose-dependent
effect during the second treatment period (p,0.05).
Body composition
The increaseinlean and fat massoftheinfarctgroupsdid notshow
any significant difference between surgery and start of treatment (day
28) and the body composition was similar in all groups (average: 36 g
fat,248 glean).Placebo-treatedratsgained nofat,butonlylean body
mass during the treatment period. The ghrelin compounds induced
both fat and lean mass gain, but to a different extent (Figure 4). The
ratio of fat to lean gain was 0.9060.07 for BIM-28131 at 50 nmole/
kg/d, while at 500 nmole/kg/d it was 0.7660.07 for BIM-28131,
0.6860.12 for BIM-28125, and 0.4860.05 for native ghrelin
(ANOVA: p=0.0001, figure 5).
Cardiac function
As expected, the hearts of infarcted animals were significantly
heavier than those of sham rats even if they were adjusted to size
(tibia length, Table 2). The left ventricle displayed some signs of
compensatory hypertrophy (data not shown), resulting in similar
weight in sham and infarct rats. The septum weights were higher
in all groups treated with ghrelin compounds, except for BIM-
28125 at 50 nmole/kg/d (p=0.073), as compared to placebo or
sham animals (ANOVA 0.086). The right ventricle of infarct
animals were heavier than sham rats, but displayed no differences
within the infarct groups (Table 2).
Cardiac function was analysed with echocardiography and
hemodynamics (Table S1). Overall no beneficial effect of
treatment with ghrelin analogues was seen. However, a small,
non-significant improvement of BIM-28131 was observed in the
ejection fraction (p=0.127) and fractional shortening (p=0.137,
Figure 6).
Expression of MAFbx and MuRF-1
Both E3-ligases which are thought to be the rate limiting step of
the ubiquitin-protesome system, were up-regulated in gastrocne-
mius muscle by myocardial infarction (Figure 7). Expression of
Figure 4. Effect of ghrelin compounds on body composition assessed by NMR scanning. A) absolute gain of fat mass and lean body mass.
B) relative gain of fat and lean body mass compared to start of treatment. *: p,0.05, **: p,0.01, ***: p,0.001 compared to placebo.
doi:10.1371/journal.pone.0026865.g004
Figure 5. Ratio of fat and lean gain induced by ghrelin
compounds. A ratio of 1 means equal fat and lean body mass gain.
BIM-28131 (50 nmole/kg/d) has the most benificial ratio of all
compounds and doses tested.
doi:10.1371/journal.pone.0026865.g005
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28125 and 500 nmole/kg/d BIM-28131 only (Figure 7 A), while
MuRF-1 was down-regulated to sham levels by all compounds
with the exception of the 500 nmole/kg/d BIM-28125 group
(Figure 7 B).
Discussion
A therapeutic role for the peptide hormone ghrelin has been
proposed in patients suffering from end-stage heart failure and
cardiac cachexia [15]. Ghrelin has been shown to increase
appetite and body weight, and it is thought to have beneficial
effects on cardiac function [14,15] [18]. The increase in food
intake is thought to be independent of the GHS-receptor [19].
While Nagaya et al. [14] have shown weight and cardiac effects on
rat ghrelin, they have not assessed the body composition changes
of treatment. The present study was designed to characterize the
effects and the efficacy of two peptide ghrelin analogues (BIM
28125 and BIM-28131) compared to native human ghrelin (BIM-
28142), which only differs from rat ghrelin by two residues and
shows the same pharmacological activity on the rat receptor as the
rat peptide [20].
This study demonstrates that all three compounds at the
500 nmole/kg/d and also BIM-28131 at the 50 nmole/kg/d
induce weight gain superior to that of the placebo and even of
non-infarcted animals treated with placebo. A beneficial effect of
ghrelin on body weight has also been described in human and rat
[21] [22]. The overall weight gain significantly decreases in all
high dose groups with time. This is a quite physiological
phenomenon, because the growth rate of the animals slows, as
the animals get older. However when the data is adjusted to the
gain seen in the placebo group taken as baseline growth/gain, it is
remarkable that human ghrelin actually shows strong tolerance
effects compared to BIM-28125 and BIM-28131, which keeps its
potency (approx. 2.5 fold increase in body weight gain vs placebo
in both time periods).
While the placebo treated infarcted animals could not built up
energy reserves, i.e. fat, and only gained lean mass, the animals
treated with ghrelin compounds gained fat and lean mass.
Contrary to earlier reports [23] human ghrelin induced more
lean than fat gain, whereas the ratio of gains seen in animals
receiving BIM-28131 was balanced, which may reflect differences
in the affinity of the compounds to the GHSR type 1a and typ 1b
Table 2. heart weight adjusted to size (tibia length).
Sham
Placebo Placebo
BIM-28125
50 nmole/kg/d
BIM-28131
50 nmole/kg/d
hum ghrelin
50 nmole/kg/d
BIM-28125
500 nmole/kg/d
BIM-28131
500 nmole/kg/d
hum ghrelin
500 nmole/kg/d
ANOVA
(infarct
groups)
Heart weight
[mg]
1055623 1381639 1322636 1454647 1402635 1479645 1509652 1459646 0.103
Heart/tibia
[mg/cm]
26765 364611 342610 370612 361610 384613 389614 367612 0.124
LV/tibia
[mg/cm]
13264 13263 12565 127641 2 3 641 3 5 651 2 7 641 2 6 65 0.523
RV/tibia
[mg/cm]
47629 8 668 5 679 9 689 5 671 0 1 691 0 0 689 4 67 0.695
Sep/tibia
[mg/cm]
55625 5 636 0 626 6 636 2 626 5 636 5 646 2 62 0.086
LA/tibia
[mg/cm]
7.760.5 23.961.8 21.862.2 23.361.6 23.861.7 21.661.9 28.962.4 26.562.5 0.077
RA/tibia
[mg/cm]
8.760.5 19.362.3 16.961.6 19.061.9 18.862.2 22.461.9 22.161.9 21.162.1 0.260
LV: left ventricle, RV: right ventricle, Sep: Septum, LA: left atrium, RA: right atrium.
doi:10.1371/journal.pone.0026865.t002
Figure 6. Ghrelin compounds have no effect on cardiac
function. A small, non-significant improvement of left ventricular
(LV) ejection fraction (EF) and fractional shortening (FS) was seen in the
50 nmole/kg/d BIM-28131 group compared to placebo.
doi:10.1371/journal.pone.0026865.g006
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MAFbx protein levels in gastrocnemius muscle of rats with
myocardial infarction compared to sham surgery, which has also
been described for the myocardium [16]. This was reversed in
animals treated with all three ghrelin compounds at low dose and
from the BIM-28131 high dose group. This likely reflects higher
activity of the UPS in skeletal muscle of infracted rats, which is
normalized by treatment with ghrelin compounds. A similar
finding of a ghrelin receptor agonist has been reported in a severe
burns model [25].
The increase in fat mass may have important consequences in
the therapy of cardiac cachexia patients, as it has been shown
recently that the fat content is inverse related to survival in
hemodialysis patients [26]. This effects has also been observed in
approx. 500 chronic heart failure patients, where the 12-month
mortality was highest (14%) in the low fat mass quartile (4–21%)
and lowest (3%) in the high fat mass quartile (.30%) [27]. Also a
reduction of major clinical events has been reported in CHF
patients with a BMI.30 group and even stronger in the high fat
group [28]. Lean mass gain on the other hand can be seen as an
improvement of the quality of life, as more lean mass, i.e. muscle,
is bound to lead to a greater physical capacity [29]. Hence, the
ideal cachexia treatment should aim at raising both, fat and lean
mass, which all three compounds used in this study are capable of,
but only BIM-28131 shows this effect in the low dose and induces
a more balanced gain of fat and lean mass. Using a lower dose in a
clinical setting potentially reduces side effects and is therefore
favourable.
Previous studies have shown that ghrelin induces food intake
[30] by activating neuropeptide Y neurons in the hypothalamic
arcuate nucleus [31], an effect that has also been observed in CHF
patients after intravenous administration of ghrelin [15]. Contrary
to those reports a 4-day rat study did not find an increased food
intake but still found an increased body weight [32]. This study
shows an increase in food consumption in all high dose groups, as
well as the low dose BIM-28131 group compared to placebo.
Generally, the food intake was declining during the study, but that
may be accounted for by the physiological slowing growth rate of
the young animals.
Previous reports have suggested a strong clinical improvement
of cardiac function by ghrelin in, both, human and animal
studies [14] [15]. In these previous studies human ghrelin
significantly increased cardiac output, ejection fraction and
fractional shortening and decreased systemic vascular resistance.
In the small, open-label human trial few side effects were
observed [15]. In our study, however, no beneficial effects of
ghrelin compounds were seen on heart function. Although a
positive trend was observed in ejection fraction and fractional
shortening for BIM 28131. This may be due to the continuous
infusion of the compounds in our study compared to the three
times daily injection used in the other studies, which would
produce peaks of compounds in plasma. These peaks may have
differential effects on downstream targets compared to a steady
compound level.
Conclusion: Ghrelin and related analogues are potent inducers
of weight gain in a heart failure situation. BIM-28131 is superior to
BIM-28125 and human ghrelin in weight gain and induces a
balanced gain of fat and lean tissue, while normalizing the
expression of MuRF-1 and MAFbx. This may make BIM-28131
an ideal candidate for the development of a novel therapy strategy
to treat severe heart failure and cardiac cachexia.
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Figure 7. Induction of E-3 ubiquitin ligases MuRF-1 and MAFbx
in gastrocnemius muscle by myocardial infarction. Low dose of
the compounds reduced MuRF-1 and MAFbx expression. Treatment
with high dose BIM-28131 and human ghrelin reduced MuRF-1 (A) and
only treatment with high does BIM-28131 reduced MAFbx (B). *: p,0.05
vs sham.
doi:10.1371/journal.pone.0026865.g007
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